Chairman: Prof. Oliver Distler

Department of Rheumatology, University Hospital Zurich
Gloriastrasse 25, 8091 Zürich, Switzerland

1989-1996 Medical student at the University of Erlangen, Germany and Duke University, North Carolina, USA

2004/2005 Specialization in Internal Medicine

2006 Specialization in Rheumatology

2012 Certificate of Advanced Studies in Healthcare Management, University of St. Gallen, Switzerland

1996-1997 Intern, Department of Internal Medicine II, Bamberg, Germany

1997-1998 Resident, Department of Internal Medicine I, University of Regensburg, Germany

1998-2002 Fellow, Center of Experimental Rheumatology, University of Zurich, Switzerland

2002-2003 Fellow, Department of Clinical Immunology, University of Zurich, Switzerland

2004-2006 Fellow, Department of Rheumatology, University of Zurich, Switzerland

2006-2009 Attending Physician (Oberarzt), Department of Rheumatology, University of Zurich, Switzerland

2006-2013 Privatdozent, University of Zurich, Switzerland

2009-2016 Senior Attending Physician (Leitender Arzt) and Director Scleroderma Program, Department of Rheumatology, University of Zurich, Switzerland

2012 Visiting Professor, University of Gothenburg, Sweden

2013-2016 Professor ad personam of Inflammatory Rheumatology, University of Zurich, Switzerland

2015-2017 Adjunct Professor, University of Florence, Italy

2015 Visiting Professor, Stanford University, USA

2016 Full Professor of Rheumatology, University of Zurich, Switzerland

2016 Professor, University of Zurich, Switzerland; Chairman Department of Rheumatology, University Hospital Zurich and Balgrist University Hospital, Switzerland
2015-2018 Sinergia-SNF (coordinating PI). Topic: Novel Imaging and Therapeutic Tools in Systemic Sclerosis.
2015-2018 Hochspezialisierte Medizin-2 (HSM-2). Topic: Gezielte und interdisziplinäre Behandlung schwerer immunvermittelter Erkrankungen.
2016-2018 SNF Project Grant. Topic: Long non-coding RNAs in systemic sclerosis and other fibrotic diseases.
2016-2018 Swisslife- Foundation. Topic: Development of systemic autoimmunity through Fra2 mediated regulatory T cell deficiency.
2016-2018 Helmut Horten Foundation. Topic: The role of microRNA-125b in systemic sclerosis.
2016-2019 Skintegrity, Flagship Project UZH-ETH. Topic: Systemic sclerosis.
2017-2018 Kurt und Senta-Herrmann-Foundation. Topic: Development of systemic autoimmunity through Fra2 mediated regulatory T cell deficiency.
2017-2018 Baugarten Foundation. Topic: Einfluss von körpereigenen Knorpelabbauprodukten auf die Hämatopoese und deren Relevanz in schmerzhaft entzündlichen Knochenmarkveränderungen.
2017-2020 Foundation for Research in Science and the Humanities at the University of Zurich (STwF).Topic: The role of the bromodomain proteins in arthritis susceptibility and synovial biology.
2018-2021 Personsonalized Health and Related Technologies – Swiss Personalized Health Network (PHRT-SPHN) Grant. Topic: PRECISE: Identification of biomarkers and therapeutic targets in inflammatory disease immunotherapy by high-dimensional single cell analysis and cluster proteomics.

Master, PhD and MD students: 14 Master/MD/PhD students between 1998 and 2017 (successfully completed Master/MD/PhD thesis); Current: Fabian Brennecke, Sebastian Burgener, Rucsandra Dobrota, Caroline Evers, Jasmin Hérnandez, Matthew Kassier, Dzulija Kiceva, Anastasiia Kozlova, Simon Kuster, Geraldine Lautenbach, Fiona Martin, Chantal Meier, Thomas Moser, Dominic Moret, Elena Pachera, Florian Renoux, Michal Rudnik, Janine Schniering, Noah Schweizer, Mara Stellato, Kabriya Charles Thavaratnam, Michele Trussardi.

Postdocs and senior group leaders: 8 postdocs/senior group leaders between 2001 and 2017; Current: Przemyslaw Blyszczuk, Stefan Dudli, Mojca Frank-Bertoncelj, Suzana Jordan, Astrid Jüngel, Gabriela Kania, Emmanuel Karouzakis, Kerstin Klein, Britta Maurer, Michel Neidhart, Caroline Ospelt, Masaya Yokota, Wanlong Wu.

  • Clinical examination course (MeF): Internal Medicine, 8 hours per year
  • Human biology block course (MNF): Pathophysiology and molecular biology of vegetative systems, 2 x 1.5 weeks/year
  • Basic clinical lecture series (MeF): Infectious diseases and immunology, 2 hours front lectures per year
  • Adcanced clinical lecture series (MeF): Differential diagnosis of the musculosceletal system –Rheumtology, 8 hours front lectures/year
Since 2012 Editorial Board Annals of the Rheumatic Diseases
Since 2013 Secretary and Board Member of EUSTAR (EULAR Scleroderma Trials and Research Group)
Since 2014 President Scientific Committee Swiss Society of Rheumatology (SGR)
Since 2014 President and/or Co-President of Scientific Advisory Boards of three randomized controlled clinical phase 2/3 registration trials in systemic sclerosis
Since 2014 Member of Scientific Advisory Board of multiple additional phase 2/3 randomized controlled clinical trials and investigator-initiated proof of concept studies in systemic sclerosis
Since 2015 Scientifc Advisory Board GILS (Gruppo Italiano per la Lotta alla Sclerodermia) Foundation
Since 2016 Editorial Board Journal of Scleroderma and Related Disorders
Since 2016 Scientifc Advisory Board of the AbbVie Rheumatology Grant
Since 2016 Scientific Advisory Board Member of the Hartmann Müller Foundation
Since 2016 Senate Member of SAMW (Swiss Academy of Medical Sciences), Representative of Medical Faculty, University of Zurich
Since 2017 Board Member, SCQM Foundation (Swiss Clinical Quality Management in Rheumatic Diseases)

Active memberships in scientific societies, fellowships in renowned academies
Since 2016: Member Walter-Siegenthaler-Gesellschaft für Fortschritte in der Inneren Medizin

Organisation of conferences

Involved in the organization of 19 conferences, including chair and scientific organization committee of the following important meetings:

  • Abstract selection committee of the American College of Rheumatology (ACR) and abstract chair of the section “Pathophysiology of scleroderma and related diseases, Annual ACR meeting 2006-2007
  • Co-Chair and Co-organizer of the congress „Controversies in connective tissue diseases”, Florence 2007, Zurich 2008 and London 2009
  • Co-Chair and Co-organization of the congress „Expert Meeting on pulmonary hypertension”, Frankfurt 2010
  • Steering committee Member of the Systemic Sclerosis World Congress, Florence 2010, Madrid 2012, Rome 2014, Lisbon 2016, Bordeaux 2018
  • International Advisory Board for the Annual European Workshop of Rheumatology Research (EWRR) since 2011
  • Program Committee of Member the Annual European League against Rheumatism (EULAR) congress Berlin 2012, London 2013 and Paris 2014
  • President Annual Meeting of the Swiss Society of Rheumatology (SGR) 2014-2018
  • Program Committee of the EUSTAR educational course on systemic sclerosis since 2015

Major prizes, awards, fellowships
2001 Young Investigator Research Career Award of the University of Zurich
2002 European Workshop of Rheumatology Young Investigators Award
2002 Academic Exchange Travel Award of ACR and EULAR
2003 Abbott Award Basic Science

2005: Warnery Award of the Swiss Society for Rheumatology

2009: Pfizer Award Rheumatology/Clinical Immunology

Our research focus is on systemic sclerosis (SSc), which is a difficult to treat chronic autoimmune disease with high morbidity and mortality. Skin fibrosis is the hallmark of this disease. Our research program spans from a preclinical program focusing on the identification and characterization of key molecules and intracellular signaling cascades that are driving the disease process to a translational and clinical program with emphasis on precision medicine and phase 2/3 clinical trial design. Our Center has been awarded a EULAR Center of Excellence due to the scientific achievements in these areas.

In our preclinical program, we could show that signaling via the Serotonin receptor 2b on fibroblasts is a key mechanism to promote fibrosis in a TGF-b dependent manner in vitro, but also in different animal models of skin fibrosis in vivo (Dees et al, 2011). These promising results led us to perform a proof of concept clinical study in patients with SSc using biomarkers as the primary endpoint. In the investigator-initiated study, we found strong effects on key features of fibrosis confirming the animal studies (Distler et al, paper in preparation). Collaborating with industry, we now designed a phase 3 registration study which has been positively evaluated by the regulatory agencies EMA and FDA and will start later in 2018. We could improve clinical trials design of this study be using biostatistical modeling with large databases, which we co-initiated and organized (Maurer et al 2015, Dobrota et al 2016).

Another focus in the laboratory are epigenetics and non-coding RNAs. In SSc, we have focused on miRNAs as a class of non-coding RNAs. We were the first to show that miR-29 is down regulated in SSc by TGF-β, PDGF-B, and IL-4 and directly contributes to fibrosis by targeting collagen mRNA [Maurer et al, 2010]. This resulted in a patent filed for the use of miR-29 in scleroderma. Furthermore, we have characterized additional miRNAs such as miR-193b and miR-145 as important posttranscriptional regulators in SSc contributing to diverse pathophysiological processes like vasculopathy and fibrosis (Iwamoto et al 2014, Vettori et al, in preparation). Recently, we have identified the novel long non-coding RNA H19X as a key mediator of TGFb profibrotic effects in a variety of mesenchymal cells. Knock-down of H19X completely prevented the profibrotic effects of TGFb. RNA Sequencing and ATAC-Seq showed that these effects are likely mediated by modification of the transcription factor AP-2. H19 X was found to be upregulated in tissues of several fibrotic diseases including SSc (Pachera et al, manuscript in preparation).

Our laboratory has been centrally involved in the identification and characterization of animal models of SSc. For example, there was until recently no animal model available that resembled the vascular changes in human SSc. The further characterization and validation of the Fra-2 tg mice by our groups enabled the use of this animal model as a preclinical model for the vascular (and fibrotic) manifestations of SSc, and it is now one of the most frequently used preclinical model for SSc. We could show that these mice develop skin fibrosis likely mediated by initial apoptosis of endothelial cells, and that the vascular lesions largely resembles finding observed in human SSc tissues (Maurer et al, 2009; Maurer et al, 2012). In addition, we showed that VEGF tg mice develop skin fibrosis in a dose-dependent manner and are more susceptible to inducible models of fibrosis such as the bleomycin model than control wt mice (Maurer et al, 2014).

Translational of our findings into potential clinical applications has always been a focus of our research. We had observed that some of our targets for intervention showed promising results in the animal models, but did not show effects in human proof of concept studies. Using the example of tyrosine kinase inhibitors (Distler, 2007), we could show that the anti-fibrotic effects were strongly depending on the level of activation of the targets, and that in the human disease target activation was often much lower than in the used animal models (Maurer et al, 2013). This lead to change in the use of animal models in preclinical characterization and to updated recommendations how to use animal models in SSc (Jordan et al, 2013). It also highlighted the importance of precision medicine in this disease and led to the development of a molecular imaging program. In this Sinergia funded program, we could recently show that molecular imaging using SPECT or PET/CT in mouse models of SSc allows individual identification of activated pathway involving folate receptor beta (FR-β) and integrin avβ3, paving the way for precision medicine approached against this pathways (Schniering et al, in preparation).

Publication summary

Total number of primary research publications: 179

Citations: 10’936, H-Index: 53 (Web of Science, February 2018)

 

Ten most important papers

(1) Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O. Imatinib mesylate decreases the production of extracellular matrix and prevents the development of experimental dermal fibrosis. Arthritis Rheum 2007, 56:311-22. Citations: 247

This preclinical proof of concept study for inhibition of fibrosis by targeting tyrosine kinases led to several clinical studies in systemic sclerosis and other fibrotic diseases.

(2) Distler JH, Jüngel A, Huber LC, Seemayer CA, Reich III CF, Gay RE, Michel BA, Fontana F, Gay S, Pisetsky DS, Distler O. The induction of matrix metalloproteinase             and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. P Natl Acad Sci USA 2005, 102:2892-7. Citations: 167

In this report, the strong functional effects of microparticles on the destructive potential of rheumatoid arthritis synovial fibroblasts were described leading to a series of publications in high rank journals in this field.

(3) Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JHW, Gay S, Distler O. miR-29 is a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010, 62:1733-43. Citations: 258

This was the first report on disturbed expression and regulation of microRNAs in systemic sclerosis and their contribution to the development of fibrosis, also filed as a patent.

(4) Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, Michel BA, Gay RE, Muller-Ladner U, Matucci-Cerinic M, Plate KH, Gassmann M, Gay S. Uncontrolled   expression of vascular endothelial growth factor and its receptors leads to insufficient kin angiogenesis in patients with systemic sclerosis. Circ Res 2004, 95:109-16. Citations: 194

The first in depths analysis on the differential expression and regulation of vascular endothelial growth factor and its key role in the disturbed angiogenesis of systemic sclerosis.

(5) Dees C, Akhmetshina A, Reich N, Jüngel A, Beyer C, Krönke G, Zwerina J, Reiter R, Alenina N, Maroteaux L, Gay G, Schett G, Distler O*, Distler JHW.* Platelet-derived serotonin links vascular disease and tissue fibrosis. *contributed equally. J Exp Med 2011, 208:961-72. Citations: 114

This comprehensive analysis of serotonin receptor 2 signaling in systemic sclerosis led to an investigator-initiated clinical proof of concept study from my group with positive results. Currently, a large scale phase III randomized placebo-controlled international multicenter registration study is initiated with me as the global PI.

(6) Distler O, del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay RE, Michel BA, Brühlmann P, Müller-Ladner U, Gay S, Matucci-Cerinic M. Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor (VEGF) are a feature of earliest disease stages and are associated with the absence of fingertip ulcers, Arthritis Res Ther 2002; 4:R11. Citations: 173

This study established for the first time the dysbalance of angiogenic and angiostatic factors in systemic sclerosis and associated these findings with vascular manifestations of the disease.

(7) Distler JH, Jüngel A, Michel BA, Gay RE, Matucci-Cerinic M, Marti HH, Gay S, Distler O. Dermal hypoxia increases the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007; 56:4203-4215. Citations: 91

Herein, we could show that hypoxia is an independent driver of fibrosis leading to a vicious circle of fibrosis accumulation and hypoxia. These findings had important impact on the concept of fibrosis as a multifactorial disease that might require multitargeted treatments.

(8) Maurer B, Graf N, Michel BA, Müller-Ladner U, Czirják L, Denton CP, Tyndall A, Metzig C, Lanius V, Khanna D, Distler O; on behalf of EUSTAR co-authors. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis. 2015; 74(6):1124-31. Citations: 28

This study defined novel inclusion criteria for randomized controlled clinical trials in systemic sclerosis taking advantage of the large EUSTAR database, which was co-founded by me together with several other colleagues. Several of the ongoing phase three registration trials are using these novel inclusion criteria.

(9) Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O; on behalf of the EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015; 74(6):1188-94. Citations: 78

Using innovative clinical trial design, we could gather evidence for effects of the anti-CD20 therapy Rituximab in patients with systemic sclerosis.

(10) Maurer B, Busch N, Jüngel A, Pileckyte M, Gay RE, Michel BA, Schett G, Gay S, Distler J, Distler O. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009; 120:2367-76. Citations: 57

This was the first description of the Fra-2 tg mouse model as a model of systemic sclerosis. Fra-2 tg mice are nowadays frequently used mouse models for the disease.

Segretary: Anna Maria Hoffmann- Vold

First name: Hoffmann-Vold, Anna-Maria
Date of birth: 12.02.1974
Nationality: Norwegian, German

2011-2014  PhD University of Oslo (UiO)
1999-2002 Medical doctoral degree (dissertation), Humboldt University of Berlin (HU)
1993-2000 Medical school, HU Berlin

Current position
2019- PI for the ReSScue study funded by KLINBFORSK
2018- Postdoc researcher, Department of Rheumatology, Oslo University Hospital, University of Oslo, Oslo, Norway,

Research positions
2015-2018 Post doc researcher, Dept of Rheumatology, OUH (Prof. Ø. Molberg)
2015-2016 Visiting researcher, Dept of Medicine and Immunology, UCLA, USA
2011-2014 PhD candidate, Dept of Rheumatology, OUH (Prof. Ø. Molberg)
2008-2011 Researcher 50%, Dept of Rheumatology, OUH (Prof. JT Gran)
1998-2002 PhD candidate, Dept of Hematology, HU Berlin (Prof. Possinger)

Fellowships (past 3 years)
2017  Multi-dimensional analyses of the Norwegian, nationwide Systemic Sclerosis cohort; a novel and unique approach to precision medicine (the     Nor-PreSScision project), HSØ
2015 – 2016 Fellowship for microbiome research (Patient organization)
Research grant for research abroad University (UiO)
Research grant Unger-Vetlesen Grant for research abroad at the UCLA

Awards and grants(past 3 years)
2019 –  EULAR clinical abstract award
2018 –  Best poster award at the annual meeting of the Norwegian
2015 – Best abstract award at national rheumatology meeting
Oslo University (UiO) grant for research abroad
Norwegian Women’s Public Health Association
Unger-Vetlesen Grant for microbiome research at the UCLA

2015-2016 David Geffen School of Medicin, Dept of Pulmonary disease and immunology, University of California (UCLA), Los Angeles, USA

Helene Marjavara Inselseth: “Borderline pulmonal hypertensjon ved systemisk sklerose (SSc)” (Student
project, UiO, main supervisor)
Main supervisor for cand med Håvard Fretheim on his Ph.D. project on “Utprøving av ny behandling for systemisk sklerose”, 2017-20 (financed by Norwegian Women’s Public Health Association).
Main supervisor for cand med Anders Heiervang Tennøe on his Ph.D. project on “Identification of novel tools for cardiopulmonary risk prediction in SSc”, 2016-19 (financed by Extrastiftelsen).
Co supervisor for Henriette Didriksen on her PhD on “Approaching the potential roles of chemokine CCL21 in Systemic Sclerosis”

Principle investigator for the national multicenter clinical trial on fecal microbiota transplantation (FMT) in SSc (2019-2022), National coordinator and principle investigator in an international multicenter clinical phase III studies in systemic sclerosis with interstitial lung disease (2017), leader of the evaluation committee for a PhD thesis (University Oslo) (2016), liaison and consultancies within this field with other disciplines inside and outside the OUH, participation in strategy meetings, publicity work, teaching and education of students/residents/peers, organizing of workshops/meetings/patient information events

2019 Head of SSc research at OUH
2019 Member of the scientific committee for the scleroderma world congress
2018 Head (and Founder) of the Norwegian SSc study group
2018 Member of the scientific committee for the Scandinavian rheumatology conference 2020
2018 Steering committee of the Nordic PH vision group
2018 Member of the Norwegian Pulmonary hypertension study group
2017 Norwegian representative for “Standing Committee of Investigative Rheumatology” for EULAR
2016 Chair of the SSc study group at OUH
2015 Founder of Nordic interested SSc experts (NiSScE)2011 Member of the EUSTAR (EULAR scleroderma trial and research)
2003 Member of NFR (Norwegian Association for Rheumatology)

Individual scientific expert activities
Consultancies, participation in strategy meetings, invited speaker (SSc world congress,
Swiss national rheumatology meeting), invited moderator (ACR), Peer-viewing (selected)
for journals: American Journal of Respiratory and Critical Care medicine, Annals of the
Rheumatic Diseases, Frontiers Immunology, Arthritis and Rheumatology, Arthritis Care
and Research, Journal of Rheumatology and Scand J Rheum, RMD open, Frontiers in
Immunology; abstracts for congresses (selected): Congress of Rheumatology hosted by
EULAR (Europe), Guest Editor Front Immunology

I am a member of the Rheumatology research group at OUH since 2011 and the head of the SSc research group since 2018. The group focuses its activities on clinical and translational research related to serious connective tissue diseases, particularly systemic sclerosis, myositis and MCTD. My recent projects include prediction of disease worsening of systemic sclerosis (SSc), lung fibrosis progression, assessment of the 2013 EULAR/ACR criteria for SSc, exploratory study on SSc-related pulmonary arterial hypertension (PAH), studies assessing biomarkers correlated with cardiopulmonary dysfunction in SSc and mechanistic study on the potential role of gut microbiota as environmental factors in SSc. I have recently established the unique nationwide Norwegian SSc-cohort (Nor-SSc) with wide national collaboration and led the completed a collaborative, investigator driven pilot randomized clinical trial on fecal microbiota transplantation in SSc.

Hoffmann-Vold AM, Distler O, Murray B, Kowal-Bielecka O, Khanna D, Allanore Y; EUSTAR and SCTC collaborators. Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open. 2019 Mar 4;5(1):e000826. doi: 10.1136/rmdopen-2018-000826. eCollection 2019
Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019 Jul;78(7):979-987. doi: 10.1136/annrheumdis-2018-214816
Volkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, Clements PJ, Hoffmann-Vold AM, Furst DE, Kim G, Goldin J, Elashoff RM. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. J Rheumatol. 2019 Feb 15. pii: jrheum.180441. doi: 10.3899/jrheum.180441.
Elhai M, Hoffmann-Vold AM, Avouac J, Pezet S, Cauvet A, Leblond A, Fretheim H, Garen T, Kuwana M, Molberg Ø, Allanore Y. Performance of candidate serum biomarkers for systemic sclerosis-interstitial lung disease. Arthritis Rheumatol. 2019 Jan 9. doi: 10.1002/art.40815
Hoffmann-Vold AM, Weigt SS, Palchevskiy V, Volkmann E, Saggar R, Li N, Midtvedt Ø, Lund MB, Garen T, Fishbein MC, Ardehali A, Ross DJ, Ueland T, Aukrust P, Lynch JP 3rd, Elashoff RM, Molberg Ø, Belperio JA. Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. PLoS One. 2018 Nov 20;13(11):e0206545. doi: 10.1371/journal.pone.0206545. eCollection 2018.
Tennøe AH, Murbræch K, Andreassen J, Fretheim H, Garen T, Gude E, Andreassen, AK, Aakhus S, Molberg Ø, Hoffmann-Vold AM. Left ventricular diastolic dysfunction predicts mortality in a large unselected systemic sclerosis cohort. J Am Coll Cardiol. 2018 Oct 9;72(15):1804-1813. doi: 10.1016/j.jacc.2018.07.068
Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, Ye S, Siegert E, Allanore Y, Hoffmann-Vold AM, Distler O. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis. 2018 Sep;77(9):1326-1332. doi: 10.1136/annrheumdis-2018-213201
Hoffmann-Vold AM, Hesselstrand R, Fretheim H, Ueland T, Andreassen AK, Brunborg C, Palchevskiy V, Midtvedt Ø, Garen T, Aukrust P, Belperio JA, Molberg Ø. CCL21 as a potential serum biomarker for pulmonary arterial hypertension in Systemic Sclerosis. Arthritis Rheumatol. 2018 Apr 24. doi: 10.1002/art.40534.
Hoffmann-Vold AM, Fretheim H, Midtvedt Ø, Kilian K, Angelshaug M, Chaudhary A, Gunnarsson R, Brunborg C, Garen T, Andreassen AK, Gude E, Molberg Ø. Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort. Rheumatology (Oxford). 2018 Mar 1;57(3):480-487. doi: 10.1093/rheumatology/kex435
Volkmann ER, Hoffmann-Vold AM, Chang YL, Jacobs JP, Tillisch K, Mayer EA, Clements PJ, Hov JR, Kummen M, Midtvedt Ø, Lagishetty V, Chang L, Labus JS, Molberg Ø, Braun J. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol. 2017 Apr 1;4(1):e000134. doi: 10.1136/bmjgast-2017-000134. eCollection 2017.
Hoffmann-Vold AM, Midtvedt Ø, Tennøe A H, Garen T, Lund MB, Aaløkken TM, Andreassen AK, Brunborg C, Taraldsrud E and Molberg Ø. Cardiopulmonary disease development in anti-RNA polymerase III positive Systemic Sclerosis; comparative analyses from an unselected, prospective patient cohort. J Rheumatol. 2017 Jan 15. pii: jrheum.160867. doi: 10.3899/jrheum.160867
Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM. Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017 Apr 4. doi: 10.1002/art.40114. Epub ahead of print
Hoffmann-Vold AM, Heiervang Tennøe A, Garen T, Midtvedt Ø, Abraityte A, Aaløkken TM, Lund MB, Brunborg C, Aukrust P, Ueland T, Molberg Ø. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression and reduced survival in Systemic Sclerosis. Chest. 2016 Aug;150(2):299-306. doi: 10.1016/j.chest.2016.03.004. Epub 2016 Mar 18.
Molberg Ø, Hoffmann-Vold AM. Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis. Curr Opin Rheumatol. 2016 Nov;28(6):613-8. doi: 10.1097/BOR.
Elhai M, Avouac J, Hoffmann-Vold AM, Ruzehaji N, Amiar O, Ruiz B, Brahiti H, Ponsoye M, Fréchet M, Burgevin A, Pezet S, Sadoine J, Guilbert T, Nicco C, Akiba H, Heissmeyer V, Subramaniam A, Resnick R, Molberg Ø, Kahan A, Chiocchia G, Allanore Y. OX40L blockade protects against inflammation-driven fibrosis. Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3901-10. doi: 10.1073/pnas.1523512113. Epub 2016 Jun 13
Hoffmann-Vold AM, Aaløkken TM, Lund MB, Garen T, Midtvedt Ø, Brunborg C, Gran JT, Molberg Ø. Predictive Value of Serial High-Resolution Computed Tomography Analyses and Concurrent Lung Function Tests in Systemic Sclerosis. Arthritis Rheumatol. 2015 May;67(8):2205-12.
Reiseter S, Molberg Ø, Gunnarsson R, Lund MB, Aalokken TM, Aukrust P, Ueland T, Garen T, Brunborg C, Michelsen A, Abraityte A, Hoffmann-Vold AM. Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. Arthritis Res Ther. 2015 Aug 28;17(1):231.
Hoffmann-Vold AM, Gunnarsson R, Garen T, Midtvedt O, Molberg O. Performance of the 2013 ACR/EULAR classification criteria for systemic sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease. J Rheumatol. 2015, Jan;42(1):60-

Treasurer: Dr. Armando Gabrielli

1975-1978:  Instructor, Istituto di Patologia Medica e Metodologia Clinica, University of Ancona

1977: Assistant Resident, Istituto di Patologia Medica e Metodologia Clinica, University of Ancona

1982:  Visiting Professor – Dpt. of Laboratory Medicine, University of  South Carolina, Charleston, USA

  • Lecturer, School of Specialization in Haematology

1984-1989: Lecturer, School of Specialization in Immunohaematology

1984-1992:  Lecturer, School of Specialization in Internal Medicine

1985-1985: Visiting Scientist- Max Planck Institute fur Biochemie, Munchen

1985-1985: Fellowship of the European Molecular Biology Organization

1988-1988: Visiting Scientist- Max Planck Institute fur Biochemie, Munchen

1992-2000: Associate Professor in Internal Medicine, Istituto di Clinica Medica Generale, Ematologia ed   Immunologia Clinica, University of Ancona, Italy

1996:  Director of Laboratory of Molecular Medicine, Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica University of Ancona, Italy

2000: Full Professor of Internal Medicine, Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica Università Politecnica delle Marche, Italy.

2004: President, Fondazione di Medicina Molecolare e Cellulare, Ancona, Italy

2005: Chairman Division of Clinica Medica, Ospedali Riuniti, Ancona, Italy

2013: Chairman Full Professor of Internal Medicine, Dipartimento di Scienze Cliniche e Molecolari, Clinica Medica, Università Politecnica delle Marche, Italy.

2013: Head of the Division of the Laboratory of Clinical Immunology

2016: Member of the Scientific Board of EUSTAR (EULAR Scleroderma Trials and Research)

Luchetti MM, Paroncini P, Majlingova P, Frampton J, Mucenski M, Svegliati Baroni S, Sambo P, Introna M, Gabrielli A. Characterization of the c-myb responsive region of the human type I collagen a2 chain gene. J Biol Chem 278, 1533-41, 2003

Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement in scleroderma.  Clin Exp Rheumatol 21 (S) 15-18, 2003

Luchetti MM, Sambo P, Mjilingova P, Svegliati Baroni S, Paroncini P, Peri G, Introna M, Stoppacciaro A, Mantovani A, Gabrielli A. Scleroderma fibroblasts constitutively express the long pentraxin PTX3. Clin Exp Rheumatol  22, 66-72, 2004

Del Rosso A, Cinelli M, Guiducci S, Pignone A, Fibbi G, Margheri F, Gabrielli A, Giacomelli R, Coppini A, Del Rosso M, Matucci Cerinic M. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.. Rheumatology 44:1255-62, 2005

Monti G, Pioltelli P, Saccardo F, Campanini M, Candela M, Cavallero G, De Vita S, Ferri C, Mazzaro C, Migliaresi S, Ossi E, Pietrogrande M, Gabrielli A, Galli M, Invernizzi F. Incidence and characteristics of Non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis c virus-related symptomatic mixed cryoglobulinemia. Arch Intern Med 165, 101-105, 2005

Nesci S, Iliescu A, Buffi O, Sista T,  Luchetti M, Gabrielli A, Rinaldi G. A novel HLA-Cw*6 allele, Cw*160102, identified by clonino and sequencing. Tisse Antigens 65: 580-1 2005

Caggiari L, Simula MP, Marzotto A, Caragnano A, Luchetti M, Gabrielli A, De Re V Identification of a novel human DRB1*13 allele by sequence-based DRB typing Tissue Antigens  66:246-7. 2005

Bandinelli F, Bartoli F,Perfetto F, Del Rosso A, Pignone A, Guiducci S, Fatini C, Generini S, Gabrielli A, Giacomelli A,  Maddali Bongi S, Abbate R, Del Rosso M, Matucci Cerinic M The fibrinolytic system components are increased in Systemic Sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). Clin Exp Rheumatol. 23: 671-7 2005

Guiducci S, Del Rosso A, Cinelli M, Perfetto F, Livi R, Rossi A, Gabrielli A, Giacomelli R, Iori N,  Fibbi G, Del Rosso M, Matucci Cerinic M. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis Arthritis Res Ther 7, 1244-1253, 2005.

Dziadzio M, Anastassiades CP, Hawkins PN, Potter M, Gabrielli A, Brough GM, Black CM, Denton CP. From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. Clin Rheumatol 25; 3-15, 2005

Svegliati Baroni S, Cancello R, Sambo P, Luchetti M, Paroncini P, Orlandini G,  Discepoli G, Paterno’ R, Santillo MR, Cozzo I, Silvana Cassano, Avvedimento EV, Gabrielli A Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK 1-2. Amplification of ROS-ERK-Ras signalling in scleroderma fibroblasts. J Biol Chem 280; 36474-82, 2005

Moroncini G,  Mangieri M ,  Morbin M,  Mazzoleni G, Ghetti B, Gabrielli A, Williamson RA, Giaccone G,   Tagliavini F  Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody. Neurobiology Dis 23; 7171-724,2006

Svegliati Baroni S, Santillo MR Bevilacqua F, Luchetti M, Spadoni T, Mancini M , Fraticelli P, Sambo P, Funaro A , Kazlauskas A, Avvedimento EV, Gabrielli A Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis . N Engl J Med 354; 2667-76, 2006

Gabrielli A Svegliati Baroni S, Avvedimento EV, Stimulatory autoantibodies to the PDGF receptor in scleroderma (Correspondence). N Engl J Med 354; 1279, 2006

Del Papa N, Quirici N, Soligo D, Cortina M, Scavullo C, Borsotti C, Maglione W, Comina DP, Vitali C, Fraticelli P, Gabrielli A, Cortelezzi A, Lambertenghi-Deliliers G Bone marrow endothelial progenitors are defective in systemic sclerosis Arthritis Rheum 54; 2605-15, 2006

Cinelli M, Guiducci S; Del Rosso A; Pignone A; Del Rosso M; Fibbi G; Serratì S; Gabrielli A; Giacomelli R; Piccardi N, Matucci Cerinic, M Piascledine modullates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis syniviocytes  Scan J Rheumatol 2006, 35:346-50.

Ferrera F, Rizzi M, Sprecacenere B, Balestra P, Sessarego M, Di Carlo A, Filaci G, Gabrielli A Ravazzolo R Indiveri F AIRE gene polymorphisms in Systemic Sclerosis associated with Autoimmune Thyroiditis Clin Immunol 122; 13-7, 2007

Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, Moroncini  G, Bacigalupo A, Leoni P, Avvedimento EV,  Gabrielli A.  Stimulatory aotoantibodies to the PDGF receptor in patients with estensive chronic graft-versus-host disease, Blood 110: 237-241,2007

 

Kopecki Z, Luchetti M, Adams D, Strudwick X, Mantamadiotis T, Stoppacciaro A, Gabrielli A, Ramsay R, Cowin A Collagen loss and impaired woud healing is associated with c- Myb deficiency J Pathol 211; 351- 61, 2007

Danieli MG, Calcabrini L, Marchetti AL, Calabrese V, Pettinari L, Massaccesi C, Gabrielli A, Danieli G La terapia con immunoglobuline endovena nelle malattie autoimmuni. Rec Prog Med 98: 322-326, 2007

De Re V, Caggiari L, Simula MP, De Vita S, Mazzero C, Lenzi M, Galli M, Monti G, Ferri C, Zignego AL, Gabrielli A, Sansonno D, Dammacco F, Libra M, Sacchi N, Salamini R, Spina M, Tirelli U, Cannizzaro R, Dolcetti R. Role of HLA Class II in HCV-related disorders Ann N Y Acad Sci 1107: 308-318, 2007

Gabrielli A, Svegliati S, Moroncini G, M. Luchetti, C. Tonnini, Avvedimento EV. Stimulatory Autoantibodies to the PDGF receptor: a link to fibrosis and a pathway for novel therapeutic targets  Autoimmunity Rev 7; 121-126, 2007

Gabrielli A, Svegliati A, Moroncini G, Avvedimento EV Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 19, 640-645, 2007

Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen F, Riemkasten G, De Vita S, Morganti A, Berkani O, Guillevin L. Long-term effects of Bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 67; 1222-28, 2008

Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento   EV Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited. Sem Immunopathol 30; 329-37, 2008

 

Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Matucci-Cerinic M, Gabrielli A and EUSTAR Co-authors  Geographic variation of disease manifestations in systemic sclerosis – a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base. Ann Rheum Dis 68; 856-62, 2009

Distler HWJ, Allanore Y, Avouac J, Giacomelli R, Guiducci S, Moritz F, Akhmetshina A, Walzer U, Gabrielli A, Muller-Landner U, Tyndal A, Matucci-Cerinic M, Distler O. EUSTAR statement and recommendations on endothelial precursor cells in systemic sclerosis. Ann Rheum Dis 68, 163-168, 2009

Krieg T, Hunzelmann N, Gabrielli A, Jablonska S. Scleroderma. Eur J Dermatol. 2008; 18(2):213-4.

Gabrielli A, Avvedimento EV, Krieg T. Scleroderma.  N Engl J Med 360: 1989-2003, 2009

Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulins add on treatment with mycophenolate mofetil in severe myositis. Autoimmunity Rev  9: 124-7, 2009

Danieli MG, Marchetti A, Monteforte F, Calabrese V, Pettinari L, Gabrielli A. Splenic microcalcifications in systemic lupus erythematosus. Lupus 18: 570-1, 2009

 

 

Martucci F, Acutis P, Mazza M, Nodari S, Colussi S, Corona C, Barocci S, Gabrielli A, Caramelli M, Casalone C, Moroncini G. Detection of typical and atypical bovine spongiform encephalopathy and scrapie prion strains by prion protein motif-grafted antibodies. J Gen Virol. 90:1048-53, 2009

 

Giuliodori G, Fraticelli P, bartolini M, Cagnetti C, Baruffaldi R, Rocchi MBL, Provinciali L, Gabrielli A, Silvestrini M. Cognitive and cerebral hemodynamic impairment in scleroderma patients. Eur J Neur 16:1285-90, 2009

Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabrielli A, Bacigalupo A. Imatinib for refractory chronic Graft-versus-Host disease with fibrotic features. Blood 114: 700-718, 2009;

Gabrielli A, Moroncini G, Avvedimento EV. Autoantibodies against PDGF receptor in scleroderma (correspondence) Arthritis Rheum  60; 3521-3522, 2009

Avvedimento EV, Gabrielli A Stiff and tight skin: a rear window into fibrosis without inflammation. Science Transl Med. 2010 Mar 17;2(23):23ps13.

Avouac J, Walker U, Tyndall A, Gabrielli A et al Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 37:1488-501, 2010

Bocchino ML, Agnese S, Fagone E, Svegliati S, Grieco D, Vancheri C, Gabrielli A, Sanduzzi A, Avvedimento EV. Involvement of reactive oxygen species in the phenotypic characterization of primary lung fibroblasts from idiopathic pulmonary fibrosis patients PLoS One 2010; 5: e14003

 

Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L, Muller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M, Gabrielli A. EUSTAR Group Preliminary criteria for the very, early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis 70; 476-81 2011

 

Smaldone S, Olivieri J, Gusella L, Moroncini G, Gabrielli A Ramirez F. Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts Fibrogenesis & Tissue Repair 2011, 4:8.

 

Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O’Connell D, Vazquez-Abad MD, Denton CP. Modified-release sildenafil reduces Raynaud’s attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 63; 775-782, 2011

 

Pietrogrande M, DeVita S, Zignego A, Gabrielli A et al. Recommendations for the management of mixed cryoglobulinemia syndrome in epatitis C virus- infected patients. Autoimmunity Rev 10;  444-454, 2011

Danieli MG, Pettinari L, Moretti R, LoGullo F, Gabrielli A Subcutaneous immunoglobulins in polymyositis and dermatomyositis: a novel application. Autoimmunity Rev  10; 144-149, 2011

Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Berena L, Airo P, Inanc M, Ullman S, Balbir-Gurman A, Sierakowski S, Allanore Y, Czirjak L, Riccieri V, Giacomelli R, Gabrielli A, Riemekasten G, Matucci-Cerinic M, Farge D, Hunzelmann N, Van den Hoogen FHJ, Vonk MC  Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres Ann Rheum Dis 70; 1788-1792, 2011

De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A, Ferri C, Ferraccioli GF, Quartuccio L, Corazza L, De Marchi G, Casals MR, Voulgarelis M, Lenzi M, Saccardo F, Fraticelli P, Mascia MT, Sansonno D, Cacoub P, Tomsic M, Tavoni A, Pietrogrande M, Zignego AL, Scarpato S, Mazzaro C, Pioltelli P, Steinfeld S, Lamprecht P, Bombardieri S, Galli M Preliminary classification criteria for the cryoglobulinemic vasculitis. Ann Rheum Dis 70; 1183-1190, 2011

 

Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Denton C, Furst D Carreira P, Czirjak L, Distler O, , Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger T, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk M, Chung L, Clements P, Collier D, Csuka ME, Jimenez S, Merkel P, Seibold J, Silver R, Steen V, Tyndall A, Matucci-Cerinic M, Pope JE, Khanna D. Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care & Res 2012; 64: 351-357;

De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C,Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012 64: 843-53.

Bartoloni E, Alunno A, Bistoni O, Bizzaro N, Migliorini P, Morozzi G, Doria A, Mathieu A, Lotzinker M, Allegri F, Riccieri V, Alpini C, Gabrielli A,  Tamponio  M, Gerli  R Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti- cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmunity Rev 11; 815-820, 2012

Quartuccio L, Isola M, Corazza L, Maset M, Monti G, Gabrielli A, Tzioufas A, Ferri C, Ferraccioli G, Ramos-Casals M, Voulgarelis M, Lenzi M, Mascia MT, Sansonno D, Cacoub P, Tomsic M, Tavoni A, Pietrogrande M, Zignego AL, Scarpato S, Pioltelli P, Steinfeld S, Lamprecht P, Bombardieri S, Galli M, De Vita S. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol 30; 48-52, 2012

 

Gabrielli A, Svegliati S, Moroncini G, Amico D New Insights into the role of oxidative stress in scleroderma fibrosis Open J Rheumatol  6; 87-95, 2012

Bandinelli F, Del Rosso A, Gabrielli A, Giacomelli R, Bartoli F, Guiducci S, Matucci Cerinic M.  CCL2, CCL3 and CCL5 chemokines in systemic sclerosis the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol 30; S44-9, 2012

Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M, Zultak M, Matucci-Cerinic M; DUO Registry investigators Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis. 71(5):718-21, 2012

Menditto VG, Lucci M, Polonara S, Pomponio G, Gabrielli A. Management of minor head injury in patients receiving oral anticoagulant therapy: a prospective study of a 24-hour observation protocol. Ann Emerg Med. 59:451-5, 2012

Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento  EV, La Vecchia C, Negri E, Gabrielli A. Scleroderma and cancer risk: systematic review and meta-analysis of observational studies” Rheumatology  52, 143-54, 2013

Orciani M, , Svegliati S, Gorbi S, Spadoni T, Lazzarini R, Regoli F, Di Primio R, Gabrielli A  Alterations of ROS pathway in scleroderma begin at stem cell level. J Biol Reg Homeost. Agents 27, 211-24, 2013

 

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden R, Medsger TA Jr, Carreira P, Riemekasten G, Clements P, Denton C, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes M, van Laar J, Seibold JR, Czirjak L, Steen V, Inanc M, Kowl-Bielecka O, Müller-Ladner U, Valentini G, Veale D, Vonk M, Walker U, Chung L, Collier D, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu V, Jimenez S, Kahaleh B, Merkel P, Sierakowski S, Silver R, Simms R, J Varga J, Pope JE.  2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against rheumatism Collaborative Initiative Arthritis Rheum 65, 2737-47, 2013

Campanati A, Moroncini G, Ganzetti  G, Pozniak KN, Goteri G, Giuliano A, Martina E,  Liberati G, Gabrielli A, Offidani A  Adalimumab modulates angiogenesis in psoriatic skin.  Eur J Inflamm 1, 489-498, 2013

Moroncini G, Mori S, Tonnini C, Gabrielli A. Role of viral infections in the etiopathogenesis of systemic sclerosis. Clin Exp Rheumatol 31, 3-7, 2013

 

Cuccioloni M, Moroncini G, Mozzicafreddo M, Pozniak KN, Nacci G, Grieco A, Paolini C, Tonnini C, Funaro A, Angeletti A, Gabrielli A. Biosensor-based Binding Assay for Platelet-Derived Growth Factor Receptor-α Autoantibodies in Human Serum J Anal Bioanal Tech S7: 010; 2013

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden R, Medsger TA Jr, Carreira P, Riemekasten G, Clements P, Denton C, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes M, van Laar J, Seibold JR, Czirjak L, Steen V, Inanc M, Kowl-Bielecka O, Müller-Ladner U, Valentini G, Veale D, Vonk M, Walker U, Chung L, Collier D, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu V, Jimenez S, Kahaleh B, Merkel P, Sierakowski S, Silver R, Simms R, J Varga J, Pope JE.  2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against rheumatism Collaborative Initiative. Ann Rheum Dis 72:1747-55, 2013

Olivieri A, Cimminiello MMC, Corradini P, Mordini N, Fedele R, Selleri C, Onida F, Patriarca F, Pavone E, Svegliati S, Gabrielli A, Bresciani P, Nuccorini R, Pascale S, Coluzzi S, Pane F, Poloni A, Olivieri J, Pane F, Leoni P, Bacigalupo A Long term outcome and prospective validation of NIH response criteria in 39 patients receiving Imatinib for steroid-refractory chronic GVHD. Blood 122, 4111-8, 2013

 

Fattal I, Shental N, Molad Y, Gabrielli A, Pokroy-Shapira E, Oren S,  Livneh A, Langevitz P, Pauzner R, Sarig O, Gafter U, Domany E, Cohen IR.  Epstein-Barr virus antibodies mark systemic lupus erythematosus and scleroderma patients negative for anti-DNA. Immunology. 141, 276-85. 2014

 

Danieli MG, Moretti R, Gambini S, Paolini L, Gabrielli A Open-label study on treatment with 20% subcutaneous IgG administration in Polymyositis and Dermatomyositis. Clin Rheumatol 33,  531-6, 2014

 

Danieli MG, Gelardi C, Pedini V, Moretti R, Gabrielli A, Logullo F. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. Autoimmun Rev 13,1182-8, 2014

 

Moroncini G, Pomponio G, Dziadzio M, Paci della Costanza O, Alessandra Pierfederici A, Ferretti L, Giuseppe Pupita G, Luca Salvolini L, Andrea Giovagnoni A, Gabrielli A Myocardial perfusion defects in scleroderma detected by contrast-enhanced cardiovascular magnetic resonance. La Radiologia Medica 119, 885-94, 2014

 

 

Donati A, Damiani E, Luchetti MM, Domizi R, Scorcella C, Carsetti A, Gabbanelli V, Carletti P, Bencivenga R, Vink H, Adrario E, Piagnerelli M,  Gabrielli A, Pelaia P, Ince C.  Microcirculatory effects of the transfusion of leukodepleted or non-leukodepleted red blood cells in septic patients: a pilot study. Crit Care 18, R33, 2014

 

Maurer B, Graf N, Michel BA, Müller-Ladner U, László Czirják, Denton C, Tyndall A, Baron M, Metzig C, Lanius V, Khanna D, Distler O   Gabrielli A and EUSTAR co-authors Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 74, 1124-31, 2015

 

Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M, Tyndall A, Matucci-Cerinic M, Denton CP, Distler O, Gabrielli A, van Laar J, Mayes M, Steen V, Seibold JR, Clements P, Medsger TAJr17, Carreira PE, Riemekasten G, Chung L,. Fessler BJ, Merkel P, Silver R, Varga J, Allanore Y, Mueller-Ladner U, Vonk MC, Walker UA, Cappelli S, Khanna D. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria J Clin Epidemiol 67, 706-14, 2014

Quartuccio L, Isola M, Corazza L, Ramos-Casals M, Retamozo S, Ragab GM, Zoheir MN, El-Menyawi MA, Salem MN, Sansonno D, Ferraccioli G, Gremese E, Tzioufas A, Voulgarelis M, Vassilopoulos D, Scarpato S, Pipitone N, Salvarani C, Guillevin L, Terrier B, Cacoub P, Filippini D, Saccardo F, Gabrielli A, Fraticelli P, Sebastiani M, Tomsic M, Tavoni A, Mazzaro C, Pioltelli P, Nishimoto N, Scaini P, Zignego AL, Ferri C, Monti G, Pietrogrande M, Bombardieri S, Galli M, De Vita S. Validation of the classification criteria for cryoglobulinaemic vasculitis.Rheumatology (Oxford). 53, 2209-13, 2014

EULAR Textbook on Systemic Sclerosis Ed Eric Hachulla, L Czirjak BMJ Autoantibodies, autoimmunity Masataka Kuwana, Armando Gabrielli pp 88-96, 2014

 

Svegliati S, Marrone G, Pezone A, Spadoni T, Grieco A, Moroncini G, Grieco D, Vinciguerra M, Agnese S, Jungel A, Distler O., Musti AM, Gabrielli A, Avvedimento EV. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the WNT inhibitor WIF-1 in systemic sclerosis and fibrosis. Science Signal 7,ra84, 2014

 Nobili L. Albani L, Gabrielli A, Moroncini G.  Reactivation of hepatitis B virus infection associated with anti- tumor necrosis factor –a therapy. J Antivir Antiretrovir 6, 3, 2014

Danieli MG, Gambini S, Pettinari L Logullo F, Veronesi G, Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-Centre long term follow-up study. Autoimmunity Rev 13, 1048-54, 2014

Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, Gerli R, Lunardi C, Bombardieri S, Malorni W,  Corvetta A, Moroncini G,  Gabrielli A  on behalf of “Imatinib in Scleroderma Italian Study Group” Low-dose Oral Imatinib in the Treatment of Systemic Sclerosis Interstitial Lung Disease unresponsive to cyclophosphamide. A Phase II Pilot Study. Arthritis Res Therapy 16:R144, 2014

Lonati PA, Brembilla NC, Montanari  E, Fontao L, Gabrielli A, Vettori S, Valentini G, Laffitte E; Kaya G, Meroni PL, Chizzolini C High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis”. PLoS one 9, e105008, 2014

 

Fattal I, Rimer J, Shental N, Molad Y, Gabrielli A, Livneh A, Sarig O, Goldberg I, Gafter U, Domany E, Cohen IR.  Pemphigus vulgaris is characterized by low IgG reactivities to specific self-antigens along with high IgG reactivity to desmoglein 3. Immunology 143:374-80, 2014

 

Del Papa N, Di Luca G, Sambataro D, Zaccara E, Maglione W, Gabrielli A, Fraticelli P, Moroncini G, Beretta L, Santaniello A, Sambataro G, Ferraresi R, Vitali C. Reply to J. Magalon et al. Cell Transplant  24, 2669-70, 2015

Moroncini G, Grieco A, Nacci G, Paolini C, Tonnini C, Katarzyna N. Pozniak1, Cuccioloni M, Mozzicafreddo M, Silvia Svegliati S, Angeletti M, Kazlauskas A, Avvedimento EV, Funaro A, Gabrielli A. Epitope specificity determines pathogenicity and detectability of anti-PDGFRa autoantibodies in systemic sclerosis  Arthritis Rheumatol 67; 1891–1903; 2015

Jordan S, Distler JHW, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O, , Gabrielli A EUSTAR rituximab study group. Effects and safety of Rituximab (RTX) in Systemic sclerosis: an analysis from the European Scleroderma Trial and Research group (EUSTAR). Ann Rheum Dis 74, 1188-94, 2015

 

Fattal I, Shental N, Ben-Dor S, Molad Y, Gabrielli A, Pokroy-Shapira E, Oren S, Livneh A, Langevitz P, Zandman-Goddard G, Sarig O, Margalit R, Gafter U, Domany E, Cohen IR. Guanine polynucleotides are self-antigens for human natural autoantibodies and are significantly reduced in the human genome. Immunology 146:401-10, 2015

 

 

Bonifazi M, Francesca Bravi F,  Gasparini S, La Vecchia C, Gabrielli A, Wells A, Renzoni E Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies. Chest 147, 778-91,2015

 

Damiani E, Adrario  E, Luchetti MM, Scorcella C, Carsetti A, Mininno N, Pierantozzi S, Principi T, Strovegli D, Bencivenga R, Gabrielli A, Romano R, Pelaia P, Ince C, Donati A. Plasma free haemoglobin and microcirculatory response to fresh or old red blood transfusions in sepsis. PLoS One 10, e0122655, 2015

 

Donzelli G, Carnesecchi G, Amador C, di Tommaso M, Filippi L, Caporali R, Codullo V, Riccieri V, Valesini G, Gabrielli A, Bagnati R, McGreevy KS, De Masi S, Matucci Cerinic M Fetal programming and systemic sclerosis. Am J Obstet Gynecol 213: 839.e1-8, 2015

Del Papa N, Di Luca G, Sambataro D, Zaccaro E, Maglione W, Gabrielli A, Fraticelli P, Moroncini G, Beretta L, Santaniello A, Sambataro G, Vitali C. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with Systemic sclerosis Cell transplant 24, 2297-305, 2015

Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, Gabrielli A, Pomponio G Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO Syndrome with a pathophysiology targeted therapy. A case report. Experimental Hematology & Oncology 4:3, 2015

Iudici M, Moroncini G, Cipriani P, Giacomelli R, Gabrielli A, Valentini G Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? Autoimmun Rev. 14, 575-578, 2015

 

Fraticelli P, De Vita S, Franzolini N, Svegliati S, Scott C, Tonnini C, Spadoni T, Gabrielli B, Pomponio G, Moroncini G, Gabrielli A Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Clin Exp Rheumatol 33, 160-167, 2015

 

Spadoni T, Svegliati Baroni S, Amico D, Albani L, Moroncini G, Avvedimento EV, Gabrielli A. A reactive oxygen species-mediated loop maintains the increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol 67, 1611–1622, 2015

Amico D, Spadoni T, Rovinelli M, Serafini M, D’Amico G, Campelli N, Svegliati S, Gabrielli A. Intracellular free radical production by peripheral blood T lymphocytes from patients with Systemic Sclerosis: role of NADPH oxidase and ERK1/2. Arthritis Res Therapy 17, 68, 2015

Olivieri J, Manfredi L, Postacchini L, Tedesco S, Leoni P, Gabrielli A, Rambaldi A, Bacigalupo A, Olivieri A, Pomponio G. Consensus recommendations for improvement of unmet clinical needs? The example of chronic graft-versus-host disease: a systematic review and meta-analysis. Lancet Haematol 2, e297-305, 2015

Quartuccio L. et al Quartuccio L, Zuliani F, Corazza L, Scaini P, Zani R, Lenzi M, Tavoni A, Sebastiani M, Baldovino S, Urraro T, Saccardo F, Sbreglia C, Mazzaro C, Pioltelli P, Fraticelli P, Filippini D, Gabrielli A, Perrella O, Scarpato S, Roccatello D, Zignego AL, Ferri C, Bombardieri S, Pietrogrande M, Monti G, Galli M, De Vita S. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long term follow up of a randomized controlled multicenter study J of Autoimmunity 63, 88-93, 2015

Luchetti MM , Moroncini G, Escamez MJ, Svegliati Baroni S, Spadoni T, Grieco A, Paolini C, Avvedimento EV, Larcher F, Del Rio M, Gabrielli A Induction of scleroderma fibrosis in skin-humanized mice by administration of anti-Platelet-Derived Growth Factor receptor agonistic autoantibodies. Arthritis Rheumatol 68, 2263-73, 2016

 

Luchetti MM, Balloni A, Gabrielli A. Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile.Curr Drug Saf. 11:22-34, 2016

Iudici M, Moroncini G, Cipriani P, Giacomelli R, Gabrielli A, Valentini G. Comment on ‘Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?’. Autoimmun Rev 15: 202, 2016

Brembilla NC, Dufour AM, Alvarez M, Hugues S, Montanari E, Truchetet ME, Lonati P, Fontao L, Gabrielli A, Vettori S, Valentini G, Boehncke WH, Meroni P, Chizzolini C.  IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Ann Rheum Dis. 75:1697-705; 2016

Danieli MG, Gelardi C, Guerra F, Cardinaletti P, Pedini V, Gabrielli A. Cardiac involvement in polymyositis and dermatomyositis. Autoimmun Rev 15, 462-5, 2016.

López-Isac E, Campillo-Davo D, Bossini-Castillo L, Guerra SG, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, García de la Peña P; Spanish Scleroderma Group, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, de Vries-Bouwstra J, Herrick A, Worthington J, Denton CP, Fonseca C, Radstake TR, Mayes MD, Martín J Influence of TYK2 in Systemic Sclerosis susceptibility: a new locus in the IL-12 pathway” Ann Rheum Dis  75, 1521-6, 2016

López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ; Spanish Scleroderma Group, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JH, Riekemasten G, van der Helm-van Mil AH, de Vries-Bouwstra J, Magro-Checa C, Voskuyl AE, Vonk MC, Molberg Ø, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BP, Denton CP, Fonseca C, Radstake TR, Worthington J, Mayes MD, Martín J. Brief report: IRF4 newly identified as a common susceptibility locus for Systemic Sclerosis and Rheumatoid Arthritis in a cross-disease meta-analysis of Genome-wide Association Studies. Arthritis Rheumatol 68, 2338-44,2016

 Fraticelli P, Kafyeke A, Mattioli M, Martino GP, Murri M, Gabrielli A. Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with Imatinib. World Journal of Clin Cases In Press

Fraticelli P, Bagnarelli P, Tarantino G, Martino GP, Benfaremo D, Nobili L , Mandolesi A, Barbisan F, Marinelli K, Mattioli M, Murri, M, Gabrielli A Chronic hepatitis E in a patient treated with rituximab and mycophenolate mofetil for Sjogren’s syndrome Rheumatology In Press

Bianchi T, Wolcott RD, Peghetti A, Leaper D, Cutting K, Polignano R, Rosa Rita Z, Moscatelli A, Greco A, Romanelli M, Pancani S, Bellingeri A, Ruggeri V, Postacchini S, Tedesco S, Manfredi L, Camerlingo M, Rowan S,Gabrielli A Pomponio G, Recommendations for the management of biofilm: a consensus document Journal of Wound Care  25, 305-17, 2016

 

Moroncini G, Albani L, Nobili L, Gabrielli A. Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile. Curr Drug Saf 11: 44-6, 2016

Salaffi F, Fraticelli P, Carotti M, Fischetti C, Di Carlo M, Giuseppetti GM, Gabrielli A. Internal and external responsiveness of computer-aided quantification of interstitial lung disease from high resolution computed tomogrophy images in Systemmic sclerosis: comparison with visual reader-based score. Sarcoidosis vasculitis and diffuse lung disease In Press

Ciccia F, Guggino  G, Rizzo, Alessandro R, Luchetti MM, Milling S, Saieva L, Cypers H, Stampone T, Gabrielli A, Fasano A, Elewaut D, Triolo G. Dysbiosis and Zonulin up-regulation alter gut epithelial and vascular barriers in patients with Ankylosing Spondylitis. Annals Rheum Dis In Press

Svegliati S, Amico D, Spadoni T, Fischetti C, Finke D, Moroncini G, Paolini C, Tonnini C, Grieco A, Rovinelli M, Gabrielli A. Agonistic anti-PDGF receptor autoantibodies from patients with Systemic sclerosis impact human pulmonary artery smooth mucle cells in vitro. Front Immunol In Press